The U.S.-based pharmaceutical company updated its 2025 earnings guidance following strong second-quarter results and sustained demand for key therapies.
Pfizer has revised its full-year profit forecast upward after reporting stronger-than-expected financial results for the second quarter of 2025. The performance was driven by continued demand for its cardiovascular drug Vyndaqel and the anticoagulant Eliquis, alongside currency exchange gains and resilient manufacturing strategies.
The drugmaker posted adjusted earnings of 78 cents per share for the quarter ended June 29, surpassing the consensus estimate of 58 cents per share. Total revenues reached $14.65 billion, outperforming analyst expectations of $13.56 billion, as per LSEG data. The earnings included a 20-cent per share charge related to a licensing agreement with China’s 3SBio for an experimental oncology product.
According to The Economic Times, Pfizer has indicated that it will now target adjusted earnings between $2.90 and $3.10 per share for the full year, up from its earlier range of $2.80 to $3.00. The improved forecast reflects confidence in product momentum and the company’s capacity to absorb external pressures, such as tariffs or policy changes affecting drug pricing.
The company stated it has sufficient manufacturing bandwidth across its ten U.S. sites to address potential disruptions related to the 15% tariffs imposed on imports from the European Union. Pfizer is also prepared to shift some production to these domestic sites if needed, ensuring continuity in supply.
Second-quarter sales of Vyndaqel and Vyndamax reached $1.62 billion, slightly above analyst projections. Eliquis, co-marketed with Bristol Myers Squibb, delivered $2 billion in revenue, outperforming expectations of $1.94 billion. Additionally, the company noted a $22 million positive impact from foreign exchange.
While investors are tracking the potential influence of political shifts particularly vaccine-related regulatory perspectives under RFK Jr., Pfizer maintains that vaccines continue to represent approximately 20% of its total revenue. How this segment evolves will remain a point of focus in the coming quarters.
For stakeholders, Pfizer’s results underscore both market resilience and the importance of diversified product lines and flexible supply strategies in navigating policy and global economic variables.
